Price (delayed)
$39.13
Market cap
$2.22B
P/E Ratio
19.76
Dividend/share
N/A
EPS
$1.98
Enterprise value
$2.09B
Harmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. Harmony Biosciences Holdings serves
There are no recent dividends present for HRMY.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.